Evidence map›Paper›PMID 38789663›Full record

ArticleOncogene2024

E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.

Molly R Patterson, Aniek S Meijers, Emma L Ryder, Louisa M Wootton, James A Scarth, Debra Evans, Amy L Turner, Christopher W Wasson, Janne E Darell, Daisy A Theobald and 8 more

Abstract read
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Molly R PattersonSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Aniek S MeijersSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Emma L RyderSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Louisa M WoottonSchool of Life Sciences, University of Sussex, Brighton, UK.
James A ScarthSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.ORCID 0000-0002-0076-6853
Debra EvansLeeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, UK.
Amy L TurnerSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Christopher W WassonLeeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, St-James University Teaching Hospital, Leeds, UK.
Janne E DarellSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Daisy A TheobaldSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Joseph A CoganSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Claire D JamesPhilips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Miao WangSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
John E LadburySchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.ORCID 0000-0002-6328-7200
Iain M MorganPhilips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Adel SamsonLeeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, UK.
Ethan L MorganSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK. e.l.morgan@sussex.ac.uk.ORCID 0000-0002-6487-5450
Andrew MacdonaldSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK. a.macdoanld@leeds.ac.uk.ORCID 0000-0002-5978-4693

Funding

Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycleR01DE029471 · NIDCR · VIRGINIA COMMONWEALTH UNIVERSITY · PI MORGAN, IAIN · 2021 to 2025
$2.8M
Cancer Research UK (CRUK) C50189/A29039Cancer Research UK (CRUK) C57233/A22356Medical Research Council MR/S001697/1Medical Research Council MR/X009564/1NIDCR NIH HHS R01 DE029471RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M011151/1RCUK | MRC | Medical Research Foundation MR/K012665RCUK | MRC | Medical Research Foundation MR/S001697/1RCUK | MRC | Medical Research Foundation MR/X009564/1U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R01DE029471Wellcome TrustWellcome Trust (Wellcome) 105210/Z/14/ZWellcome Trust (Wellcome) 204825/Z/16/ZWellcome Trust (Wellcome) 219996/Z/19/ZWellcome Trust (Wellcome) 222371/Z/21/Z
6 · The paper itself

Abstract

Human papillomaviruses (HPV) are a major cause of malignancy, contributing to ~5% of all human cancers worldwide, including most cervical cancer cases and a growing number of anogenital and oral cancers. The major HPV viral oncogenes, E6 and E7, manipulate many host cellular pathways that promote cell proliferation and survival, predisposing infected cells to malignant transformation. Despite the availability of highly effective vaccines, there are still no specific anti-viral therapies targeting HPV or treatments for HPV-associated cancers. As such, a better understanding of viral-host interactions may allow the identification of novel therapeutic targets. Here, we demonstrate that the actin-binding protein LASP1 is upregulated in cervical cancer and significantly correlates with a poorer overall survival. In HPV positive cervical cancer, LASP1 depletion significantly inhibited the oncogenic phenotype in vitro, whilst having minimal effects in HPV negative cervical cancer cells. Furthermore, we demonstrate that the LASP1 SH3 domain is essential for LASP1-mediated oncogenicity in these cells. Mechanistically, we show that HPV E7 regulates LASP1 at the post-transcriptional level by repressing the expression of miR-203, which negatively regulates LASP1 mRNA levels by binding to its 3'UTR. Finally, we demonstrate that LASP1 expression is required for the growth of HPV positive cervical cancer cells in an in vivo tumourigenicity model. Together, these data demonstrate that HPV induces LASP1 expression to promote proliferation and survival in cervical cancer, thus identifying a potential therapeutic target in these cancers.

Indexed as

Adaptor Proteins, Signal TransducingCell ProliferationCytoskeletal ProteinsLIM Domain ProteinsMicroRNAsPapillomavirus E7 ProteinsPapillomavirus InfectionsUterine Cervical NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceAdaptor Proteins, Signal TransducingCytoskeletal ProteinsLASP1 protein, humanLIM Domain ProteinsMicroRNAsMIRN203 microRNA, humanPapillomavirus E7 Proteins

Identifiers

PMID38789663
PMCPMC11226402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.